AbbVie’s Mavyret (glecaprevir/pibrentasvir) Receives FDA’s Approval for its Expanded Indication in Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

Shots:

• The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6)
• The label expansion is based on P-IIIb EXPEDITION-8 study assessing Mavyret in treatment naïve, GT1-6 chronic HCV patients with compensated cirrhosis for 8wks., resulted in achieving sustained virologic response 12 weeks (SVR₁₂) in 98% patients
• Mavyret (qd) is a pan-genotypic, combination of glecaprevir (100mg) and pibrentasvir (40mg) and has received FDA’s approval as an 8-week, pan-genotypic treatment for the treatment-naïve HCV patients without cirrhosis in Aug’2017

Click here to­ read full press release/ article | Ref: AbbVie | Image: Independent